Ultimovacs Announces Presentation of UV1 Immune Monitoring Data at Cancer Immunotherapy Annual Meeting

Ultimovacs Announces Presentation of UV1 Immune Monitoring Data at Cancer Immunotherapy Annual Meeting

10 May 2022 08:00 CEST

* UV1 immune monitoring data from three Phase I/IIa clinical trials show
dynamic T cell responses lasting up to 7.5 years
* Measurable UV1-specific immune response in 91% of patients when combined
with checkpoint inhibitor, as compared to 82% and 67% without checkpoint
inhibitor
* Immune responses induced more rapidly when UV1 was combined with a
checkpoint inhibitor
* Development of UV1-specific immune responses associated with longer survival
time

Oslo, 10 May 2022: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage
leader in immune stimulatory vaccines for cancer, announced the presentation of
results from long-term follow-up data from three Phase I/IIa clinical. The data
is substantiating the clinical relevancy of the UV1-specific immune response and
the rationale for combining the Company's lead product, the universal cancer
vaccine UV1, with checkpoint inhibitors.

The data will be presented as a poster at the upcoming Cancer Immunotherapy
(CIMT) annual meeting in Mainz, Germany, 10-12 May 2022. The CIMT poster can be
found on the Company website.

The poster reports on a long-term follow-up study of the use of the UV1 vaccine.
The researchers looked every six months for up to 7.5 years for UV1-specific
immune responses in 51 patients enrolled in three early trials of UV1 in
malignant melanoma, non-small cell lung cancer (NSCLC) and prostate cancer.

For patients with malignant melanoma, where UV1 was combined with the checkpoint
inhibitor ipilimumab, UV1-specific immune responses occurred earlier and more
frequently than in patients with NSCLC or prostate cancer where no checkpoint
inhibitors were involved. 91% of patients with malignant melanoma showed a
detectable immune response within three months.

The high rate and rapid induction of immune responses provide support for
synergy between UV1 vaccination and checkpoint inhibition. The data further
demonstrate that UV1 vaccination leads to induction of memory T cells with an
inflammatory cytokine profile. These cytokines produced by the UV1-specific T
cells, including IFN-gamma and TNF-alpha, are considered appropriate in terms of
supporting anti-tumor activity. Immune response induction associated with longer
survival time, with a median overall survival in immune responders of 54.8
months, compared to 23.4 months in non-immune responders.

"These data - from what we believe to be the longest immune monitoring study of
a therapeutic cancer vaccine - are highly relevant to Ultimovacs' ongoing Phase
II programs in which UV1 is combined with various checkpoint inhibitors, as well
as to potential future clinical studies. The data shows that the patients' UV1-
specific immune responses may be embedded in immune memory, providing the
potential for dynamic long-term defenses against cancer" said Carlos de Sousa,
Chief Executive Officer of Ultimovacs.

==ENDS==

About Ultimovacs
Ultimovacs is an immunotherapy company developing immune-stimulatory vaccines to
treat a broad range of cancers. Ultimovacs' lead universal cancer vaccine
candidate UV1 targets human telomerase (hTERT), present in 85-90% of cancers in
all stages of tumor growth. By directing the immune system to hTERT antigens,
UV1 drives CD4 helper T cells to the tumor to activate an immune system cascade
and increase anti-tumor responses. With a broad Phase II program in five cancer
indications enrolling more than 650 patients, Ultimovacs aims to clinically
demonstrate UV1's impact in multiple cancer types, in combination with other
immunotherapies, for patients with unmet needs. Ultimovacs' second technology
approach, based on the proprietary Tetanus-Epitope-Targeting (TET) platform,
combines tumor-specific peptides and adjuvant in the same molecule and entered
Phase I studies in 2021.

For further information, please see www.ultimovacs.com or contact:

Carlos de Sousa, CEO
Email: [email protected]
Phone: +47 908 92507

Anne Worsøe, Head of IR & Communication
Email: [email protected]
Phone: +47 90686815

Mary-Ann Chang, LifeSci Advisors
Email: [email protected]
Phone: +44 7483 284 853

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to Section 5-12 in the Norwegian Securities Trading Act.

This stock exchange announcement was published by Joachim Midttun, Finance
Manager at Ultimovacs ASA, on 10 May, 2022 at 08:00 CET.

More information:
Access the news on Oslo Bors NewsWeb site

Source

Ultimovacs ASA

Provider

Oslo Børs Newspoint